ScreenerHero

RXRX Recursion Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · recursion.com
4.270USD-7.78%Mkt Cap: 2.29B $P/E: —

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and eng…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.29B USD
Enterprise Value2.00B USD
Revenue (TTM)54.86M USD
Gross Profit3.30M USD
Net Income (TTM)-644.76M USD
Revenue/Share0.11 USD
Last Price4.270 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees600
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.13
PEG—
EV/EBITDA-4.24
EV/Revenue36.45
P/S45.26
P/B2.71
EPS (TTM)-1.00
EPS (Forward)-0.90
52W Range
2.77034% of range7.180
52W High7.180 USD
52W Low2.770 USD
Profitability
Gross Margin4.45%
Oper. Margin-1759.69%
EBITDA Margin0.00%
Profit Margin-868.29%
ROE-57.01%
ROA-43.74%
Growth
Revenue Growth-60.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-371.81M USD
CapEx (TTM)8.63M USD
FCF Margin-400.13%
FCF Yield-9.59%
Net Debt-479.05M USD
Net Debt/EBITDA1.02
Balance Sheet
Debt/Equity0.07
Current Ratio5.03
Quick Ratio4.67
Book Value/Sh1.71 USD
Cash/Share1.02 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)7.217 USD
Upside (mean)+69.0%
Target Range4.000 USD – 10.00 USD
4.000+69.0% to mean10.00
# Analysts6
Ownership
Shares Out.535.34M
Float518.46M
Insiders2.04%
Institutions71.58%
Short Interest
Short Ratio11.3d
Short % Float34.95%
Short % Out.33.33%
Shares Short178.72M
Short (prev mo.)177.92M
Technical
SMA 503.455 (+23.6%)
SMA 2003.576 (+19.4%)
Beta1.03
S&P 52W Chg16.45%
Avg Vol (30d)22.54M
Avg Vol (10d)26.50M
Technical Indicators
RSI (14)58.6
MACD0.2843
MACD Signal0.2124
MACD Hist.+0.0719
BB Upper4.733 USD
BB Middle3.812 USD
BB Lower2.890 USD
BB Width48.36%
ATR (14)0.3366 USD
Vol Ratio (20d)1.62x